The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma

As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8–1.1 life years o...

Descripción completa

Detalles Bibliográficos
Autores principales: Beard, S M, Lorigan, P C, Sampson, F C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363192/
https://www.ncbi.nlm.nih.gov/pubmed/10638970
http://dx.doi.org/10.1054/bjoc.1999.0880
_version_ 1782153642803986432
author Beard, S M
Lorigan, P C
Sampson, F C
author_facet Beard, S M
Lorigan, P C
Sampson, F C
author_sort Beard, S M
collection PubMed
description As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8–1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12 800–£17 600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective. © 2000 Cancer Research Campaign
format Text
id pubmed-2363192
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23631922009-09-10 The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma Beard, S M Lorigan, P C Sampson, F C Br J Cancer Short Communication As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8–1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12 800–£17 600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective. © 2000 Cancer Research Campaign Nature Publishing Group 2000-01 1999-12-08 /pmc/articles/PMC2363192/ /pubmed/10638970 http://dx.doi.org/10.1054/bjoc.1999.0880 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Beard, S M
Lorigan, P C
Sampson, F C
The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
title The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
title_full The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
title_fullStr The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
title_full_unstemmed The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
title_short The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
title_sort cost-effectiveness of high dose chemotherapy in the treatment of relapsed hodgkin's disease and non-hodgkin's lymphoma
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363192/
https://www.ncbi.nlm.nih.gov/pubmed/10638970
http://dx.doi.org/10.1054/bjoc.1999.0880
work_keys_str_mv AT beardsm thecosteffectivenessofhighdosechemotherapyinthetreatmentofrelapsedhodgkinsdiseaseandnonhodgkinslymphoma
AT loriganpc thecosteffectivenessofhighdosechemotherapyinthetreatmentofrelapsedhodgkinsdiseaseandnonhodgkinslymphoma
AT sampsonfc thecosteffectivenessofhighdosechemotherapyinthetreatmentofrelapsedhodgkinsdiseaseandnonhodgkinslymphoma
AT beardsm costeffectivenessofhighdosechemotherapyinthetreatmentofrelapsedhodgkinsdiseaseandnonhodgkinslymphoma
AT loriganpc costeffectivenessofhighdosechemotherapyinthetreatmentofrelapsedhodgkinsdiseaseandnonhodgkinslymphoma
AT sampsonfc costeffectivenessofhighdosechemotherapyinthetreatmentofrelapsedhodgkinsdiseaseandnonhodgkinslymphoma

Ejemplares similares